DAWNZERA (donidalorsen) is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years of age and older.

Now Approved
for HAE

DAWNZERA prevents hereditary angioedema (HAE) attacks in fewer doses than ever before—one at-home subcutaneous injection every 4 or 8 weeks1

Learn more about the efficacy and safety of DAWNZERA from Autumn Burnette, MD, FACAAI, and Raffi Tachdjian, MD, MPH, leading experts in HAE, including how patients may benefit from starting or switching treatment, at our 45-minute launch broadcast on September 25, 2025.

Attend the program virtually.

Register for launch broadcast
Ionis Specialist Wearing Headset Icon

Meet with an Ionis Account Specialist

Request a visit from an Ionis specialist to learn more about DAWNZERA, and sign up to receive clinical data updates and product news.

Sign up
Paper Document Icon

See the data

View the Prescribing Information to view the full efficacy, safety, and dosing details—and see how you can get your patients started on DAWNZERA every 4 weeks1

View Prescribing Information
Ionis Every Step Support Services Logo

Access & Support

Ionis Every Step™ is a support program dedicated to help your patient start and follow your prescribed treatment plan with DAWNZERA. We help provide assistance to navigate the insurance coverage process, identify affordability programs, and support patients with information and resources throughout their treatment journey.

Get support for your patients

IMPORTANT SAFETY INFORMATION & INDICATION

CONTRAINDICATIONS

DAWNZERA is contraindicated in patients with a history of serious hypersensitivity reactions, including anaphylaxis, to donidalorsen or any of the excipients in DAWNZERA.

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions
Hypersensitivity reactions, including anaphylaxis, have been reported in patients treated with DAWNZERA. If signs and symptoms of serious hypersensitivity reactions occur, discontinue DAWNZERA and institute appropriate therapy.

ADVERSE REACTIONS

Most common adverse reactions (incidence ≥ 5%) are injection site reactions, upper respiratory tract infection, urinary tract infection, and abdominal discomfort.

INDICATION

DAWNZERA (donidalorsen) is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years of age and older.

Please see full Prescribing Information for DAWNZERA.

Reference: 1. DAWNZERA. Prescribing Information. Ionis Pharmaceuticals.